Back
Sirtex
SIR-Spheres
Resin microspheres Y-90 indicated for radioembolization treatment in unresectable Hepatocellular Carcinoma (HCC) and Primary Colorectal Cancer (mCRC) in patients refractory or intolerant to chemotherapy, through the Selective Internal Radiotherapy Technique (SIRT).
* Product sold exclusively in part of the national area (Spain).
Details of the product
The main features of the SIR-Spheres Y-90 are:
- Permanent single-use implant: It is used once to treat liver tumors.
- Uniform radiation distribution: The high number of microspheres ensures a homogeneous distribution of radiation, allowing the treatment of solitary and multifocal tumors.
- Specific density similar to red blood cells: Which allows them to be transported by the bloodstream and penetrate the tumor microvasculature.
- Controlled administration: Microspheres can be delivered slowly to maximize the amount administered and improve tumor coverage.
- Yttrium-90: Radioisotope with two safety features: minimal beta radiation penetration and a short half-life of 64.1 hours, which reduces the risk to staff and patients.
Technical Specifications
PRODUCT SPECIFICATIONS | |
Isotope | Ytro-90 (Y-90) |
Degradation product | Zirconium-90 |
Composition of the spheres | Resin |
Specific density | 1.125 g / ml |
Diameter | 32,5 μm ± 2.5 μm (range 20-60 microns) |
T1 / 2 | 64.1 h (95% disintegrates in 11 days) |
β-energy (max.) | 2.27 MeV (Iβ = 100%) |
Activity-dose conversion factor | 49.67 Gy/ (GBq x Kg) |
Penetration | 2,5 mm (medium), up to 11 mm |
Radioactivity/microsphere | 68 Bq ± 10% at calibration date and time |
Introduction | Single dose size containing 3,0 GBq ± 10% Y-90 at the date and time of calibration in 5 ml water for injection, wet-sterilized |
Number of microspheres per vial | 44,5 million |
MANAGEMENT FEATURES | |
Administration mode | Directed, slow and controlled flow with complete visibility |
Flexibility | The shipping vial can be divided into multiple treatment vials for a single patient with multiple injection sites. |